Ann: Comparative Analysis Indicates Benefits from OncoSil, page-20

OncoSil Medical (ASX:OSL)OSL has developed radiation therapy microparticles which are injected into pancreatic tumours under endoscopic ultrasound guidance.McDonald said the particles emit radiation over an 80-day period with the objective to shrink tumours enough to allow for surgical resection, which leads to longer survival.“Surgical resection rates have been shown to be about 30% in a small company study, compared to about 8.5% in a retrospective analysis of studies using chemotherapy alone but further larger studies are required,” he said.“Another benefit of the treatment is that it reduces pain, which can be a significant issue for these patients.“Oncosil’s treatment is only appropriate for patients with locally advanced cancer, which hasn’t spread to other organs, representing 20% of total patients.”McDonald said the product was already approved in Europe but there were main value drivers expected later this year including a new European label with less restrictive conditions, a limited approval in the US under a humanitarian device exemption and German health insurance reimbursement for the product and funding of a large randomised clinical trial.“The company is also enrolling two important clinical studies, which will report next year and will also be major value drivers for the business,” he said.“PANCOSIL is exploring the possibility of delivering the particles via the hepatic artery under local anaesthesia which would be more convenient than current gastric delivery under general Anaesthesia,” he said.“TRIPP-FXX, will be the company’s first randomised trial combined with the latest chemotherapy drug FOLFIRINOX.McDonald said he expected all of these factors to drive substantial revenue growth in 2025.“Only 500 units of annual sales are required to reach breakeven,” he said.